Curon Biopharma’s $149 Million Agreement With Rhizen

Wilson Sonsini Goodrich & Rosati advised Curon Biopharma on the deal.

Curon Biopharma, a Shanghai based clinical-stage biopharmaceutical company, acquired exclusive rights to Tenalisib from Rhizen Pharma of Switzerland for exploitation in greater China. Tenalisib is a next-generation dual PI3K ?/? inhibitor, which is in Phase 2 clinical development for hematological malignancies. Tenalisib has been granted U.S. FDA Fast Track Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma. Rhizen Pharma will be eligible to receive upfront and milestone payments worth up to $149.5 million, as well as tiered royalties on annual net sales of Tenalisib.

The Wilson Sonsini team that advised Curon in licensing matters related to this transaction includes Alexander Key (Picture), Karen Wong, and Kexi Wang?.

Involved fees earner: Alexander Key – Wilson Sonsini Goodrich & Rosati; Kexi Wang – Wilson Sonsini Goodrich & Rosati; Karen Wong – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Curon Biopharmaceutical;

Print Friendly, PDF & Email

Author: Ambrogio Visconti